Atypical bronchopulmonary carcinoid is a rare disease with poor prognosis. The low number of patients and their dispersion in different centers makes it difficult to draw clinical trials. The right treatment is still controversial. This study reports the clinical case of a patient with bronchopulmonary carcinoid, who showed stable disease with everolimus (an mTOR inhibitor) plus somatostatin analog after the failure of two lines of chemotherapy plus somatostatin analog. Although in literature the overall survival for metastatic bronchopulmonary carcinoid patients is 16 months, our patient reported a progression-free survival of 18 months with everolimus as third-line. Our case report underlines the importance to use new drugs that may change the disease course.